Thursday, April 23, 2026
Mizuho Raises Price Target on Revolution Medicines to $185 From $140
Mizuho raised its price target on Revolution Medicines Inc. shares (NASDAQ:RVMD) to $185 from $140 while maintaining an Outperform rating. The stock currently trades at $141.50, up 278% over the past year, though InvestingPro analysis suggests shares may be overvalued relative to its Fair Value estimate.
The firm increased its probability of success estimate for pancreatic cancer to 90% from 80% following recent clinical trial data. Mizuho also accelerated its adoption trajectory for daraxonrasib in first-line and second-line pancreatic cancer treatment. The optimism aligns with Wall Street’s broader sentiment, as analyst consensus stands at Strong Buy with price targets ranging from $116 to $215.
The adjustment follows survival benefit data from the RASolute 302 trial of daraxonrasib in second-line pancreatic cancer and updated data for the drug in first-line pancreatic cancer. The first-line data showed six-month landmark analyses for daraxonrasib regimens that compared favorably to historical gemcitabine plus nab-paclitaxel results, though progression-free survival and overall survival curves were not provided due to immature data with medians not yet reached.
Mizuho views the ongoing RASolute 303 study as well-positioned based on daraxonrasib’s performance in second-line treatment. The firm models $14 billion in risk-adjusted 2035 worldwide pancreatic cancer revenues for the drug.
The analyst reiterated the Outperform rating.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.